About enGene Holdings Inc. Warrants
https://www.engene.comenGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs.
CEO
Ronald H. W. Cooper
Compensation Summary
(Year )
Total Compensation (Unknown At The Moment)
Industry Biotechnology
Sector Healthcare
Went public February 1, 2022
Method of going public SPAC
Full time employees 56
Price Target
Target High $0
Target Low $0
Target Median $0
Target Consensus $0
Market Cap $148.47 M
52w High $2.80
52w Low $2.20
P/E 0
Volume 1.77K
Outstanding Shares 51.19M
About enGene Holdings Inc. Warrants
https://www.engene.comenGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q4-2025 | $0 | $39.31M ▲ | $-37.88M ▼ | 0% | $-0.74 ▼ | $-37.46M ▼ |
| Q3-2025 | $0 | $29.95M ▲ | $-28.99M ▼ | 0% | $-0.57 ▼ | $-27.86M ▼ |
| Q2-2025 | $0 | $27.12M ▲ | $25.82M ▲ | 0% | $0.51 ▲ | $-24.73M ▼ |
| Q1-2025 | $0 ▼ | $26.61M ▲ | $-24.62M ▼ | 0% ▲ | $-0.48 ▼ | $-23.74M ▼ |
| Q4-2024 | $480K | $17.45M | $-15.3M | -3.19K% | $-0.34 | $-14.44M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q4-2025 | $193.81M ▼ | $221.47M ▼ | $53.76M ▲ | $167.71M ▼ |
| Q3-2025 | $201.99M ▼ | $245.55M ▼ | $44.88M ▲ | $200.67M ▼ |
| Q2-2025 | $217.46M ▲ | $266.65M ▼ | $39.36M ▲ | $227.29M ▼ |
| Q1-2025 | $213.89M ▼ | $285.93M ▼ | $35.98M ▼ | $249.95M ▼ |
| Q4-2024 | $238.4M | $311.17M | $38.56M | $272.61M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q4-2025 | $-37.88M ▼ | $-24.96M ▲ | $40.5M ▲ | $1.99M ▲ | $17.53M ▲ | $-25.4M ▲ |
| Q3-2025 | $-28.99M ▼ | $-25.63M ▼ | $1.38M ▼ | $-667K ▼ | $-24.92M ▼ | $-26.34M ▼ |
| Q2-2025 | $-25.82M ▼ | $-22.95M ▲ | $17.95M ▲ | $199K ▲ | $-4.8M ▲ | $-22.99M ▲ |
| Q1-2025 | $-24.62M ▼ | $-25.7M ▼ | $-84.96M ▲ | $1K ▼ | $-110.66M ▼ | $-26M ▼ |
| Q4-2024 | $-15.3M | $-19.57M | $-125.27M | $60.16M | $-84.67M | $-19.81M |
CEO
Ronald H. W. Cooper
Compensation Summary
(Year )
Total Compensation (Unknown At The Moment)
Industry Biotechnology
Sector Healthcare
Went public February 1, 2022
Method of going public SPAC
Full time employees 56
Price Target
Target High $0
Target Low $0
Target Median $0
Target Consensus $0